**Table SIII. Quick inventory of depressive symptomatology-self report (QIDS-SR16) total score categories at each study visit**

| | Blinded treatment period | | Open-label treatment period | | |
|---|---|---|---|---|---|
| | PBO (*n* = 74) | | PBO/IXE Q4W (*n* = 65) | | |
| Severity Category | Week 0 (*Nx* = 74) *n* (%) | Week 12 (*Nx* = 64) *n* (%) | Week 24 (*Nx* = 65) *n* (%) | Week 40 (*Nx* = 64) *n* (%) | Week 52 (*Nx* = 63) *n* (%) |
| None | 49 (66.2) | 46 (71.9) | 51 (78.5) | 50 (78.1) | 54 (85.7) |
| Mild | 17 (23.0) | 10 (15.6) | 12 (18.5) | 13 (20.3) | 8 (12.7) |
| Moderate | 7 (9.5) | 6 (9.4) | 2 (3.1) | 1 (1.6) | 1 (1.6) |
| Severe | 0 | 2 (3.1) | 0 | 0 | 0 |
| Very Severe | 1 (1.4) | 0 | 0 | 0 | 0 |
| | IXE Q2W (*n* = 75) | | IXE Q2W/IXE Q4W (*n* = 74)[a] | | |
| Severity Category | Week 0 (*Nx* = 75) *n* (%) | Week 12 (*Nx* = 71) *n* (%) | Week 24 (*Nx* = 69) *n* (%) | Week 40 (*Nx* = 67) *n* (%) | Week 52 (*Nx* = 66) *n* (%) |
| None | 55 (73.3) | 66 (93.0) | 64 (92.8) | 55 (82.1) | 54 (81.8) |
| Mild | 15 (20.0) | 4 (5.6) | 3 (4.3) | 10 (14.9) | 10 (15.2) |
| Moderate | 5 (6.7) | 1 (1.4) | 1 (1.4) | 1 (1.5) | 2 (3.0) |
| Severe | 0 | 0 | 1 (1.4) | 1 (1.5) | 0 |
| Very Severe | 0 | 0 | 0 | 0 | 0 |

[a]Patients initially randomized to IXE Q2W at Week 0 who received at least 1 dose of IXE Q4W during the open-label treatment period.
Percentages were calculated as n/Nx where n is the number of patients in the specified category and Nx is the total number of patients with nonmissing values.
QIDS-SR16 categories are determined based on total score as follows: None: 0–5, Mild: 6–11, Moderate: 11–15, Severe: 16–20, Very Severe: 21–27.
IXE: ixekizumab; PBO: placebo: Q2W: every 2 weeks; Q4W: every 4 weeks; QIDS-SR16: Quick Inventory of Depressive Symptomatology-Self Report (16-items).